文献速递妇产影像

慢性高血压孕妇诊断重叠子痫前期时是否应纳入血管生成标志物

Should angiogenic markers be included in diagnostic criteria of superimposed pre-eclampsia in women with chronic hypertension?
PubMed 文献 · Ultrasound Obstet Gynecol · 2022-01-01

该研究回顾性分析了2013年1月至2019年10月间142例慢性高血压单胎孕妇疑似重叠子痫前期病例,评估血清sFlt-1、PlGF及sFlt-1/PlGF比值对重叠子痫前期的预测价值,发现sFlt-1/PlGF比值预测1周内重叠子痫前期的AUC为0.91,优于PlGF的0.86,将血管生成标志物加入传统ISSHP诊断标准可提高不良母胎结局的检出率。

要点

  • sFlt-1/PlGF比值预测1周内重叠子痫前期的AUC为0.91,优于PlGF的0.86(P=0.032)。
  • 血管生成标志物加入传统ISSHP标准使不良母体结局检出率提高35.1%(95%CrI 16.6-53.6%)。
  • 该策略对不良围产结局检出率提高20.6%(95%CrI 0.0-42.2%),但特异度下降5.7%。

核心结论

  • 在慢性高血压疑似重叠子痫前期孕妇中,将母血清血管生成标志物加入传统诊断标准可显著提高对母体和围产不良结局的预测敏感度,作者认为应考虑在评估此类孕妇时实施血管生成标志物检测。

研究设计与样本

  • 回顾性分析前瞻性收集的电子数据库数据,纳入2013年1月至2019年10月间142例慢性高血压单胎孕妇,检测母血清sFlt-1、PlGF及sFlt-1/PlGF比值,采用ROC曲线分析预测准确性,De Long检验比较AUC,二项回归评估变量与复合不良结局的关联。

诊断标准与关键数值

  • sFlt-1/PlGF比值预测1周内重叠子痫前期的AUC为0.91,PlGF的AUC为0.86(P=0.032);血管生成标志物加入传统ISSHP标准后不良母体结局检出率提高35.1%(95%CrI 16.6-53.6%)、阳性预测值提高9.6%(95%CrI 0.0-20.6%)、阴性预测值提高3.1%(95%CrI 1.3-4.9%),不良围产结局检出率提高20.6%(95%CrI 0.0-42.2%),特异度下降5.7%(95%CrI -2.3%至13.6%)。

临床应用与阅片要点

  • 作者认为在慢性高血压疑似重叠子痫前期孕妇的评估中应考虑实施血管生成标志物检测,将sFlt-1/PlGF比值等加入传统诊断标准可提高不良结局检出率。

局限性

  • ISSHP因该人群证据有限而未推荐实施血管生成标志物检测。
  • 本研究为回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Although the most recent guidance from the International Society for the Study of Hypertension in Pregnancy (ISSHP) has highlighted the role of angiogenic marker assessment in the diagnosis of pre-eclampsia (PE) in women with chronic hypertension, the ISSHP has withheld recommending its implementation due to the limited available evidence in this group of women. Therefore, we aimed to investigate the value of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) assessment in women with chronic hypertension and suspected superimposed PE.

METHODS: This was a retrospective analysis of prospectively collected data recorded in an electronic database between January 2013 and October 2019. Women with chronic hypertension and singleton pregnancy who had suspected superimposed PE were included. Superimposed PE was suspected in women presenting with worsening hypertension, epigastric pain, new-onset edema, dyspnea or neurological symptoms. The exclusion criteria were delivery within 1 week after assessment for reasons other than PE, chronic kidney disease, history of cardiac disease, fetal aneuploidy, genetic syndrome or major structural anomaly and missing pregnancy outcome. Maternal serum angiogenic markers (sFlt-1, PlGF and sFlt-1/PlGF ratio) were measured. The primary outcome was the utility of angiogenic markers in the prediction of superimposed PE. Predictive accuracy was assessed for superimposed PE diagnosed at different timepoints, including within 1 week after assessment and any time before birth. The secondary outcome was comparison of adverse maternal and perinatal outcomes between women with superimposed PE diagnosed according to the traditional ISSHP criteria and those diagnosed according to extended criteria including angiogenic markers. The predictive accuracy of each angiogenic marker was assessed using receiver-operating-characteristics-curve analysis. Area under the curve (AUC) values were compared using De Long's test. A sensitivity analysis was planned for gestational age at assessment. The association of various variables with composite adverse maternal and perinatal outcomes was assessed using binomial regression.

RESULTS: The study included 142 pregnant women with chronic hypertension and suspected superimposed PE, of whom 25 (17.6%) developed PE within 1 week after assessment, 52 (36.6%) developed PE at any timepoint before birth and 90 (63.4%) delivered without PE. Maternal serum angiogenic imbalance was associated significantly with superimposed PE diagnosed according to the ISSHP criteria within 1 week or at any time after assessment (P < 0.001 for both). The predictive accuracy of maternal serum sFlt-1/PlGF ratio for superimposed PE diagnosed within 1 week after assessment was superior to that of maternal serum PlGF level (AUC, 0.91 vs 0.86; P = 0.032). The addition of angiogenic imbalance to the traditional ISSHP diagnostic criteria was associated with an increase in the detection rate (35.1% increase; 95% credible interval (CrI), 16.6-53.6%) and positive (9.6% increase; 95% CrI, 0.0-20.6%) and negative (3.1% increase; 95% CrI, 1.3-4.9%) predictive values for composite adverse maternal outcome, with high posterior probabilities of an increase in each predictive accuracy parameter (> 99.9%, 95.6% and > 99.9%, respectively), without a meaningful decrease in specificity. The addition of angiogenic imbalance improved the detection rate for composite adverse perinatal outcome (20.6% increase; 95% CrI, 0.0-42.2%), with a high posterior probability (96.9%). There was a corresponding drop in specificity (5.7% decrease; 95% CrI, -2.3% to 13.6%), with a posterior probability of 91.8%.

CONCLUSIONS: In women with chronic hypertension and suspected superimposed PE, addition of maternal serum angiogenic markers to the traditional diagnostic criteria for superimposed PE improved significantly the sensitivity for the prediction of both maternal and perinatal adverse outcomes. Implementation of angiogenic marker assessment in the evaluation of pregnant women with chronic hypertension should therefore be considered. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Binder J, Kalafat E, Palmrich P, et al. Should angiogenic markers be included in diagnostic criteria of superimposed pre-eclampsia in women with chronic hypertension? Ultrasound Obstet Gynecol. 2022. PMID: 34165863. doi:10.1002/uog.23711

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。